Site menu

Search by ticker code:
Generic filters

Menu

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Greencross Limited (GXL) Barks Up As Profit Slides

Greencross Limited (ASX: GXL) released its 2018 financial results to the market today revealing a 7% increase in revenue.

Greencross is Australia’s largest pet company with a chain of vet clinics called Greencross and a retail chain called Petbarn.

Here are some of the highlights from its report:

  • Revenue increased by 7% to $878.7 million
  • Like for like sales growth of 4.9% (52 weeks comparison)
  • EBITDA decreased by 25% to $74.8 million (click here to learn what EBITDA means)
  • Reported profit fell by 51% to $20.7 million
  • Dividend decreased by 18% to 15.5 cents per share

According to Bloomberg, analysts were expecting Greencross to report a profit of $34.3 million. A dividend of $0.17 was also expected. Excluding ‘exceptional’ items the Greencross underlying profit was $37.2 million, investors appear pleased with what the company announced.

CEO Simon Hickey said: “FY18 was a year of substantial change for Greencross. The strength of our business model is clearly evident from the excellent like-for-like sales growth that was delivered.”

Some of the exceptional items included $21.8 million of impairments and provisions and $2.4 million of acquisition & restructuring costs.

Greencross has been working on growing its private label sales, which now represents 23% of Australian retail product sales. Private label food sales grew by 25% in FY18 in Australia.

FY19 Outlook

In the first six weeks of FY19 group like-for-like (LFL) sales were up 5.8% and total revenue growth was 8%.

Shareholders will be hoping for a better year ahead with the Greencross share price down 31% in 2018, before today’s open.

Introducing The Australian Investors Podcast

Join The Rask Group’s founder, Owen Raszkiewicz, as he profiles Australia’s best investors, founders, authors and financial thinkers. Download it free on iTunesCastboxSoundCloud or wherever you choose to listen.

itunessoundcloudcastboxdownload

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content